Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Transplant rejection Stories

2012-08-07 10:26:28

SAN ANTONIO, Aug. 7, 2012 /PRNewswire-USNewswire/ -- For kidney failure patients with living donors who are not a match, kidney paired donation offers an alternative with outstanding results, concludes a study published in this month's edition of the American Journal of Transplantation. Doctors at Methodist Specialty and Transplant Hospital published the article, "Single-Center Kidney Paired Donation: The Methodist San Antonio Experience," based on the results of a three-year study on kidney...

2012-07-30 12:57:20

Findings may affect how doctors treat allergic inflammation and organ transplant rejection A research team led by Xian Chang Li, MD, PhD, Brigham and Women's Hospital (BWH) Transplantation Research Center, has shed light on how a population of lymphocytes, called CD4+ T cells, mature into various subsets of adult T helper cells. In particular, the team uncovered that a particular cell surface molecule, known as OX40, is a powerful inducer of new T helper cells that make copious amounts of...

2012-07-19 14:21:27

ROCKVILLE, Md., July 19, 2012 /PRNewswire/ -- OriGene Technologies, Inc. and Canada's Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) today announced the selection of OriGene Technologies as a major collaboration and development partner to implement blood-based protein assays in heart and kidney transplantation. This multi-year, collaborative project funded by multiple partners will provide monitoring and predictive blood tests, based upon OriGene's extensive expertise...

2012-06-14 02:25:00

CHILLY-MAZARIN, France, June 14, 2012 /PRNewswire/ -- InGen BioSciences, specialised in the development and commercialisation of mono and multiparametric in vitro diagnostic tests announced a new exclusive partnership with Cylex Incorporated (Columbia, Maryland,...

2012-05-31 10:24:42

In the news release, Veloxis Pharmaceuticals to Present Results from a Patient Subgroup Analysis of Once-Daily LCP-Tacro(TM) in Stable African-American Kidney Transplant Patients at American Transplant Congress (ATC), issued 31-May-2012 by Veloxis Pharmaceuticals A/S over PR Newswire, we are advised by the company that the end of the second paragraph should read "second quarter of 2013" rather than "second quarter of 2012" as originally issued inadvertently. The complete, corrected release...

2012-05-31 06:28:23

HORSHOLM, Denmark, May 31, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that a subgroup analysis of African-American stable kidney transplant patients enrolled in Study 3001, a Phase 3 non-inferiority study, suggests that these patients may be safely converted from twice-daily Prograf(®) to once-daily LCP-Tacro. In addition, there was a trend toward fewer biopsy-proven acute rejections (BPARs) with LCP-Tacro compared to Prograf. The analysis will be...

Human Skin Cells Turned Into Healthy Heart Muscle
2012-05-23 09:50:33

Scientists on Wednesday reported that they have for the first time taken skin cells from heart attacks patients and turned them into healthy heart tissue that could hopefully be used to one day repair damaged heart muscle. The healthy, beating heart tissue was grown successfully in the lab from human-induced pluripotent stem cells (hiPSCs), and while scientists said they were not safe enough to put back into human patients, they appeared to work well with other cells when implanted into...

2012-05-23 02:26:04

HORSHOLM, Denmark, May 23, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it contemplates restructuring the company's operations in order to fully focus its resources on the completion of the development and subsequent commercialization of LCP-Tacro(TM), Veloxis' product candidate for the prevention of organ rejection. It is planned that a discontinuation of other pipeline activities will take place, including early phase research activities. The basis for...

2012-04-02 15:43:29

New research in mice published in the Journal of Leukocyte Biology suggests that the platelet activating factor receptor plays a role in graft-versus-host disease, a major complication of bone marrow transplants A new discovery in mice may lead to new treatments that could make bone marrow transplants more likely to succeed and to be significantly less dangerous. According to new research findings published in the Journal of Leukocyte Biology (https://www.jleukbio.org) Brazilian scientists...

2012-03-29 02:25:47

HORSHOLM, Denmark, March 29, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf® and has randomized over 540 patients at approximately 90 clinical sites around the world. "With the results of our 3001 study already complete and our 3002 study...